Patents by Inventor Richard William Titball
Richard William Titball has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200405836Abstract: This invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating the symptoms of a demyelinating condition selected from: enterotoxemia (ET), multiple sclerosis (MS), clinically definite MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), optic neuritis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), a disease or condition characterised by the increase or presence of antibodies against aquaporin-4 (AQP-4) and/or astrocyte damage, and acute disseminated encephalomyelitis (ADEM) in a human or animal subject in need.Type: ApplicationFiled: March 1, 2019Publication date: December 31, 2020Applicant: ONE HEALTH VENTURES LTDInventors: Richard William TITBALL, Monika BOKORI-BROWN, Helen MORCRETTE, Nicholas Peter LEWIS
-
Publication number: 20200384097Abstract: The invention provides a composition comprising a reduced toxicity NetB epitope polypeptide and a reduced toxicity Clostridium perfringens alpha-toxin epitope polypeptide. The composition is useful as a vaccine providing complete protection against infection by C. perfringens.Type: ApplicationFiled: August 19, 2020Publication date: December 10, 2020Inventors: Richard William Titball, Sergio Paulo Fernandes Da Costa, Filip Van Immerseel, Richard Ducatelle, Dorien Mot
-
Publication number: 20160310587Abstract: The invention provides a composition comprising a reduced toxicity NetB epitope polypeptide and a reduced toxicity Clostridium perfringens alpha-toxin epitope polypeptide. The composition is useful as a vaccine providing complete protection against infection by C. perfringens.Type: ApplicationFiled: December 18, 2014Publication date: October 27, 2016Inventors: Richard William Titball, Sergio Paulo Fernandes Da Costa, Filip Van Immerseel, Richard Ducatelle, Dorien Mot
-
Patent number: 9346860Abstract: An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthracis or variants of these, and at least one of said domains comprises domain 1 or domain 4 of PA or a variant thereof. The polypeptides of the immunogenic reagent as well as full length PA are produced by expression from E. coli. High yields of polypeptide are obtained using this method. Cells, vectors and nucleic acids used in the method are also described and claimed.Type: GrantFiled: September 26, 2012Date of Patent: May 24, 2016Assignee: The Secretary of State For DefenceInventors: Ethel Diane Williamson, Julie Miller, Nicola Jane Walker, Leslie William James Baillie, Paula Thomson Holden, Helen Claire Flick-Smith, Helen Lisa Bullifent, Richard William Titball, Andrew William Topping
-
Patent number: 8790910Abstract: A strain of Francisella species wherein a gene which encodes for part of the glutamate metabolic pathway has been inactivated, and which is able to produce a protective immune response in an animal, for use as live prophylactic or therapeutic vaccine against infection by said Francisella species. Particularly effective strains include those where the capB gene is deleted. Other embodiments of the invention describe strains which compromise a further genetic mutation wherein a gene which encodes for another component of the cell is also inactivated. Pharmaceutical compositions comprising said strains, together with methods which utilize such strains are also described and claimed.Type: GrantFiled: November 9, 2012Date of Patent: July 29, 2014Assignee: The Secretary of State for DefenceInventors: Stephen Lloyd Michell, Petra Claire Farquhar Oyston, Richard William Titball
-
Publication number: 20130164823Abstract: An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthracis or variants of these, and at least one of said domains comprises domain 1 or domain 4 of PA ro a variant thereof. The polypeptides of the immunogenic reagent as well as full length PA are produced by expression from E. coli. High yields of polypeptide are obtained using this method. Cells, vectors and nucleic acids used in the method are also described and claimed.Type: ApplicationFiled: September 26, 2012Publication date: June 27, 2013Inventors: Ethel Diane Williamson, Julie Miller, Nicola Jane Walker, Leslie William James Baillie, Paula Thomson Holden, Helen Claire Flick-Smith, Helen Lisa Bullifent, Richard William Titball, Andrew William Topping
-
Patent number: 8425913Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.Type: GrantFiled: June 6, 2011Date of Patent: April 23, 2013Assignee: The Secretary of State of DefenceInventors: Stephen John Elvin, Gareth David Healey, Ethel Diane Williamson, James Edward Eyles, Sophie Jane Smither, Mitali Sarkar-Tyson, Timothy Philip Atkins, Michelle Nelson, Richard William Titball
-
Patent number: 8323664Abstract: A strain of Francisella species wherein a gene which encodes for part of the glutamate metabolic pathway has been inactivated, and which is able to produce a protective immune response in an animal, for use as live prophylactic or therapeutic vaccine against infection by said Francisella species. Particularly effective strains include those where the capB gene is deleted. Other embodiments of the invention describe strains which comprise a further genetic mutation wherein a gene which encodes for another component of the cell is also inactivated. Pharmaceutical compositions comprising said strains, together with methods which utilize such strains are also described and claimed.Type: GrantFiled: July 25, 2007Date of Patent: December 4, 2012Assignee: The Secretary of State for DefenceInventors: Stephen Lloyd Mitchell, Petra Claire Farquhar Oyston, Richard William Titball
-
Patent number: 8313928Abstract: An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthracis or variants of these, and at least one of said domains comprises domain 1 or domain 4 of PA or a variant thereof. The polypeptides of the immunogenic reagent as well as full length PA are produced by expression from E. coli. High yields of polypeptide are obtained using this method. Cells, vectors and nucleic acids used in the method are also described and claimed.Type: GrantFiled: March 26, 2007Date of Patent: November 20, 2012Assignee: The Secretary of State for DefenseInventors: Ethel Diane Williamson, Julie Miller, Nicola Jane Walker, Leslie William James Baillie, Paula Thomson Holden, Helen Claire Flick-Smith, Helen Lisa Bullifent, Richard William Titball, Andrew William Topping
-
Patent number: 8198430Abstract: The application relates to nucleic acids which encode enzymes responsible for the production of the O-antigen of Francisella tularensis, and their use as or in the production of vaccines and in diagnosis.Type: GrantFiled: November 24, 2008Date of Patent: June 12, 2012Assignee: The Secretary of State for DefenceInventors: Joann Lisa Prior, Richard Geoffrey Prior, Paul Gareth Hitchen, Anne Dell, Richard William Titball
-
Publication number: 20110236423Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.Type: ApplicationFiled: June 6, 2011Publication date: September 29, 2011Applicant: The Secretary of State for DefenceInventors: Stephen John Elvin, Gareth David Healey, Ethel Diane Williamson, James Edward Eyles, Sophie Jane Smither, Mitali Sarkar-Tyson, Timothy Philip Atkins, Michelle Nelson, Richard William Titball
-
Patent number: 7955601Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.Type: GrantFiled: October 2, 2006Date of Patent: June 7, 2011Assignee: The Secretary of State for DefenceInventors: Stephen John Elvin, Gareth David Healey, Ethel Diane Williamson, James Edward Eyles, Sophie Jane Smither, Mitali Sarkar-Tyson, Timothy Philip Atkins, Michelle Nelson, Richard William Titball
-
Publication number: 20100266639Abstract: An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthracis or variants of these, and at least one of said domains comprises domain 1 or domain 4 of PA or a variant thereof. The polypeptides of the immunogenic reagent as well as full length PA are produced by expression from E. coli. High yields of polypeptide are obtained using this method. Cells, vectors and nucleic acids used in the method are also described and claimed.Type: ApplicationFiled: March 26, 2007Publication date: October 21, 2010Inventors: Ethel Diane Williamson, Julie Miller, Nicola Jane Walker, Leslie William James Baillie, Paula Thomson Holden, Helen Claire Flick-Smith, Helen Lisa Bullifent, Richard William Titball, Andrew William Topping
-
Publication number: 20100080828Abstract: The application relates to nucleic acids which encode enzymes responsible for the production of the O-antigen of Francisella tularensis, and their use as or in the production of vaccines and in diagnosis.Type: ApplicationFiled: November 24, 2008Publication date: April 1, 2010Applicant: The Secretary of state of DefenceInventors: Joann Lisa Prior, Richard Geoffrey Prior, Paul Gareth Hitchen, Anne Dell, Richard William Titball
-
Publication number: 20100062022Abstract: A protein derived from an outer layer of Burkholderia pseudomallei or a fragment or a variant of said protein, wherein the protein, fragment, or variant is capable of producing a protective immune response in an animal, for use in the treatment of infection by Burkholderia species. Pharmaceutical compositions comprising such proteins are also described and claimed.Type: ApplicationFiled: August 7, 2007Publication date: March 11, 2010Inventors: Sarah Victoria Harding, Mitali Sarkar-Tyson, Petra Claire Farquar Oyston, Richard William Titball
-
Publication number: 20100055123Abstract: This invention relates to proteins expressed by ABC system genes of Burkholderia pseudomallei. The proteins (or protective fragments or protective variants thereof) are protective against Burkholderia pseudomallei infection. Use of the proteins in treating Burkholderia mallei or Burkholderia pseudomallei infection and uses in the preparation of vaccines against melioidosis and glanders are described and claimed.Type: ApplicationFiled: April 13, 2006Publication date: March 4, 2010Inventors: David Neil Harland, Helen Susan Atkins, Nicola Jane Walker, Michelle Nelson, Richard William Titball, Timothy Phillip Atkins
-
Publication number: 20100047283Abstract: A strain of Francisella species in which gene FTT1564, or homologue thereof, has been inactivated, and which is able to produce a protective immune response in an animal, for use as live prophylactic or therapeutic vaccine against infection by said Francisella species. Other embodiments of the invention describe strains which comprise a further genetic mutation wherein additional genes are also inactivated. Pharmaceutical compositions comprising said strains, together with methods of preventing and treating tularemia infection, which utilise such strains, are also described and claimed.Type: ApplicationFiled: December 21, 2007Publication date: February 25, 2010Inventors: Stephen Lloyd Michell, Petra Claire Farquar Oyston, Mark Ivor Richards, Richard William Titball
-
Publication number: 20100021501Abstract: A strain of Francisella species wherein a gene which encodes for part of the glutamate metabolic pathway has been inactivated, and which is able to produce a protective immune response in an animal, for use as live prophylactic or therapeutic vaccine against infection by said Francisella species. Particularly effective strains include those where the capB gene is deleted. Other embodiments of the invention describe strains which comprise a further genetic mutation wherein a gene which encodes for another component of the cell is also inactivated. Pharmaceutical compositions comprising said strains, together with methods which utilise such strains are also described and claimed.Type: ApplicationFiled: July 25, 2007Publication date: January 28, 2010Inventors: Stephen Lloyd Mitchell, Petra Claire Farguhar Oyston, Richard William Titball
-
Publication number: 20090220548Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.Type: ApplicationFiled: October 2, 2006Publication date: September 3, 2009Applicant: The Secretary of State for DefenceInventors: Stephen John Elvin, Gareth David Healey, Ethel Diane Williamson, James Edward Eyles, Sophie Jane Smither, Mitali Sarkar-Tyson, Timothy Philip Atkins, Michelle Nelson, Richard William Titball
-
Patent number: 7572449Abstract: The use of (i) an antibody specific for Yersinia pestis F1-antigen, or a binding fragment thereof, or (ii) an antibody specific for Yersinia pestis V-antigen, or a binding fragment thereof, or a combination of (i) and (ii), in the production of a medicament for the treatment of infection by Yersinia pestis. It has been found that such treatments are effective therapies for Yersinia pestis infection. In addition, the combination produces a synergistic effect when used prophylactically.Type: GrantFiled: August 29, 2003Date of Patent: August 11, 2009Assignee: The Secretary of State for Defense in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern IrelandInventors: James Hill, Ethel Diane Williamson, Richard William Titball